Three consecutive commercial-scale drug product batches successfully produced ...

Manipulating the immune system to treat cancer has generated phenomenal responses in some patients, including complete cures, ...

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...

Operator Good morning, and welcome to the BioCryst fourth-quarter 2024 earnings call. All participants will be in listen-only mode. [Operator instructions] Please note this event is being recorded. I ...

Retinal gene therapy advancements may rewrite the book on treatments for age-related macular degeneration and diabetic eye diseases.

Robert Tighe appointed as Senior Vice President of Preclinical and Translational Sciences and Katherine Bell-McGuinn, M.D., Ph.D. appointed as Senior Vice President of Clinical Development Appointment ...

Summit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.

Inceptor Bio, a clinical-stage biotechnology company pioneering next-generation cell therapies, today announced that the first patient has been dosed in the clinical trial of IB-T101, the company's ...

PST-611, a first in class non-viral vectorized therapy expressing human transferrin, a highly potent iron regulator.

ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)——FY 2025 ORLADEYO ...

Poor eyesight is a common problem, especially as one becomes older. Is there a way to check macular degeneration in the eyes, ...

Updated TIDE-A study findings show that maintenance Bavencio with Inlyta treatment interruption is feasible in patients with ...